Zynerba Pharmaceuticals Inc. (ZYNE)

6.49
0.11 1.70
NASDAQ : Health Technology
Prev Close 6.38
Open 6.32
Day Low/High 6.27 / 6.65
52 Wk Low/High 2.75 / 16.47
Volume 112.05K
Avg Volume 735.90K
Exchange NASDAQ
Shares Outstanding 23.20M
Market Cap 143.13M
EPS -2.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Oversold Conditions For Zynerba Pharmaceuticals (ZYNE)

Oversold Conditions For Zynerba Pharmaceuticals (ZYNE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

SHAREHOLDER ALERT - Zynerba Pharmaceuticals, Inc. (ZYNE) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action And Lead Plaintiff Deadline: December 23, 2019

SHAREHOLDER ALERT - Zynerba Pharmaceuticals, Inc. (ZYNE) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action And Lead Plaintiff Deadline: December 23, 2019

NEW YORK, Oct. 29, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Zynerba Pharmaceuticals, Inc.

Shareholder Alert: Robbins Arroyo LLP Announces Zynerba Pharmaceuticals, Inc. (ZYNE) Sued For Misleading Shareholders

Shareholder Alert: Robbins Arroyo LLP Announces Zynerba Pharmaceuticals, Inc. (ZYNE) Sued For Misleading Shareholders

Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Zynerba Pharmaceuticals, Inc.

ZYNERBA CLASS ACTION ALERT: Bernstein Liebhard LLP Announces The Filing Of A Securities Class Action Against Zynerba Pharmaceuticals

ZYNERBA CLASS ACTION ALERT: Bernstein Liebhard LLP Announces The Filing Of A Securities Class Action Against Zynerba Pharmaceuticals

NEW YORK, Oct. 28, 2019 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action has been filed on behalf of investors that purchased or acquired the securities of Zynerba...

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Zynerba Pharmaceuticals, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Zynerba Pharmaceuticals, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zynerba Pharmaceuticals, Inc.

ZYNERBA CLASS ACTION ALERT: Bernstein Liebhard LLP Announces The Filing Of A Securities Class Action Against Zynerba Pharmaceuticals

ZYNERBA CLASS ACTION ALERT: Bernstein Liebhard LLP Announces The Filing Of A Securities Class Action Against Zynerba Pharmaceuticals

Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action has been filed on behalf of investors that purchased or acquired the securities of Zynerba Pharmaceuticals ("Zynerba" or the "Company") (NASDAQ:...

ROSEN, A TOP RANKED LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Zynerba Pharmaceuticals, Inc. - ZYNE

ROSEN, A TOP RANKED LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Zynerba Pharmaceuticals, Inc. - ZYNE

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Zynerba Pharmaceuticals, Inc.

Interesting ZYNE Put And Call Options For May 2020

Interesting ZYNE Put And Call Options For May 2020

Investors in Zynerba Pharmaceuticals Inc saw new options begin trading this week, for the May 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Zynerba Pharmaceuticals Is Now Oversold (ZYNE)

Zynerba Pharmaceuticals Is Now Oversold (ZYNE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Notable Wednesday Option Activity: ZYNE, TIF, DAKT

Notable Wednesday Option Activity: ZYNE, TIF, DAKT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Zynerba Pharmaceuticals Inc , where a total of 4,815 contracts have traded so far, representing approximately 481,500 underlying shares. That amounts to about 78.8% of ZYNE's average daily trading volume over the past month of 611,390 shares.

Zynerba Pharma Looks Like Bad Medicine for Investors

Zynerba Pharma Looks Like Bad Medicine for Investors

The charts make ZYNE look bearish and not particularly attractive, so avoid.

Interesting ZYNE Put And Call Options For September 20th

Interesting ZYNE Put And Call Options For September 20th

Investors in Zynerba Pharmaceuticals Inc saw new options begin trading this week, for the September 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZYNE options chain for the new September 20th contracts and identified one put and one call contract of particular interest.

Big Victory for the Bulls: Cramer's 'Mad Money' Recap (Monday 7/22/19)

Big Victory for the Bulls: Cramer's 'Mad Money' Recap (Monday 7/22/19)

Jim Cramer says that in the heart of earnings season, Wall Street analysts can make important calls that let bulls push stocks higher.

Berkshire Hathaway, Seattle Genetics, Zynerba: 'Mad Money' Lightning Round

Berkshire Hathaway, Seattle Genetics, Zynerba: 'Mad Money' Lightning Round

Jim Cramer takes a look at Berkshire Hathaway, Seattle Genetics, Zynerba Pharmaceuticals, Range Resources, Guardant Health, Danaher and more.

Don't You Dare Say 'Bubble': Cramer's 'Mad Money' Recap (Wednesday 7/10/19)

Don't You Dare Say 'Bubble': Cramer's 'Mad Money' Recap (Wednesday 7/10/19)

Jim Cramer says save the bubble-talk for the bathtub. The money investors can make in the market is real, and due to ingenuity, competitiveness and economic growth.

Planet Fitness, Allergan, Amarin: 'Mad Money' Lightning Round

Planet Fitness, Allergan, Amarin: 'Mad Money' Lightning Round

Jim Cramer weighs in on Planet Fitness, Allergan, Amarin, MPLX, Zynerba Pharmaceuticals, Schnieder National, United Parcel Service and more.

Interesting ZYNE Put And Call Options For February 2020

Interesting ZYNE Put And Call Options For February 2020

Investors in Zynerba Pharmaceuticals Inc saw new options become available this week, for the February 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

First Week Of July 19th Options Trading For Zynerba Pharmaceuticals (ZYNE)

First Week Of July 19th Options Trading For Zynerba Pharmaceuticals (ZYNE)

Investors in Zynerba Pharmaceuticals Inc saw new options become available this week, for the July 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZYNE options chain for the new July 19th contracts and identified one put and one call contract of particular interest.

No Backing Down: Cramer's 'Mad Money' Recap (Monday 5/20/19)

No Backing Down: Cramer's 'Mad Money' Recap (Monday 5/20/19)

Uncertainty over the trade war's effects on earnings make this market really hard on investors, says Jim Cramer.

Lululemon Athletica, Wayfair: 'Mad Money' Lightning Round

Lululemon Athletica, Wayfair: 'Mad Money' Lightning Round

Jim Cramer takes a look at Lululemon Athletica, Wayfair, Amazon, Intrexon, Iridium Communications, PayPal, Zscaler, Zynerba Pharmaceuticalsm and more.

Interesting ZYNE Put And Call Options For June 21st

Interesting ZYNE Put And Call Options For June 21st

Investors in Zynerba Pharmaceuticals Inc saw new options begin trading this week, for the June 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZYNE options chain for the new June 21st contracts and identified one put and one call contract of particular interest.

There Is Generally Good Action on My Screens Today

There Is Generally Good Action on My Screens Today

The price action is quite good.

I Have My Eye on This Warren Buffett Stock Amid the Choppy Action

I Have My Eye on This Warren Buffett Stock Amid the Choppy Action

Market players are more skeptical of the quick moves on U.S.-China trade news.

5 Stocks on My Radar During a Quiet Day

5 Stocks on My Radar During a Quiet Day

Sometimes dull action like this can be good for trading.

Is Apple Aggressively Buying Back Its Stock?

Is Apple Aggressively Buying Back Its Stock?

Without Apple doing so well Monday the indices would look much different.

The Action in Select Small Caps Is Encouraging

The Action in Select Small Caps Is Encouraging

It's tough to do much while we await major news events.

TheStreet Quant Rating: D- (Sell)